What Bridgewest Ventures does

Bridgewest Ventures is a New Zealand-based deep tech venture capital firm and incubator operating as the innovation engine of Bridgewest Group, a multi-billion-dollar privately held global investment firm founded in 1999 and headquartered in Miami, Florida. Established in 2020 as a Technology Incubator partner of the New Zealand government's Callaghan Innovation agency, the firm invests from Seed to Series B in deep tech ventures spanning Life Sciences, MedTech, AI/ML, Clean Tech, and Advanced Sensors. The firm combines capital deployment through the Bridgewest Venture Fund I LP (NZ$60.2M first close in May 2026, targeting NZ$100M by Q4 2026) with active hands-on incubation, embedding executive-level advisors and connecting portfolio companies to the Bridgewest Group's 25-year international network for market entry, regulatory navigation, and scaling.

The current portfolio of approximately 13 companies includes BioOra (automated CAR-T cell therapy manufacturing), Avasa (micro-artery coupler nearing FDA clearance), TheiaNova (non-invasive corneal remodeling therapy), Luminoma (skin cancer screening), Precision Chroma (3D printed chromatography columns), Nanophage (diagnostic nanorod technology), MACSO (sensory AI for agri-tech animal welfare), The TestMart (AI-driven SaaS ERP test automation), Entropeak (High-Entropy Oxide battery technology), Compostify (home-compostable bioplastics), ZealaFoam (biobased E-PLA packaging), BioViros (lentivirus vector manufacturing), and Aegros AI (AI healthcare training).

The firm's revenue model combines venture fund management (management fees and carried interest on Fund I) with equity returns from its own NZ$6M capital commitment, distributed exclusively to wholesale and institutional investors via the Catalist investor portal. The go-to-market is hybrid: direct incubation applications and ecosystem sourcing from founders, paired with investor roadshows across New Zealand, Australia (post-Australian Financial Services Licence), and the United States (Coral Gables, FL office), supported by the annual Impactful Innovation conference and partnerships with Angel Association NZ, NZ Tech Alliance, BIOTECH New Zealand, and NZ Private Capital. The firm also commissions ecosystem infrastructure such as BioValeo (CRO for personalised medicine clinical trials) to fill structural gaps in the NZ biotech stack that constrain portfolio company scaling.

Name

Bridgewest Ventures

Legal name

Bridgewest Ventures NZ LP

Website

https://bridgewest.ventures

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Bridgewest Ventures is a New Zealand-based deep tech venture capital firm and incubator that invests Seed to Series B in Life Sciences, MedTech, AI/ML, Clean Tech, and Advanced Sensors, leveraging Bridgewest Group's global network to scale portfolio companies internationally and serving wholesale investors via its NZ$100M-target Fund I.

Ownership category

akta.pro rank

Product category

Venture Capital and Private Equity

NAICS

Portfolio Management and Investment Advice (52394)

SIC

Investment Advice (6282)

akta.pro primary industry

Venture Capital Fund-of-Funds / Multi-Manager Platforms (FSANAAAJ)

Keywords

• Venture capital
• Deep tech incubator
• Startup investment
• Technology commercialization
• Portfolio management

Headquarters

HQ city

Auckland

HQ country

New Zealand

HQ region

Oceania

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Venture Fund Management: Bridgewest Venture Fund I LP is a deep-tech venture fund targeting New Zealand and Australian innovation companies. The fund attracted commitments from institutional investors, family offices, high-net-worth individuals, and international migrant investors. It is structured as an eligible investment under New Zealand's Active Investor Plus visa program. Revenue is generated through carried interest and management fees from the fund.
2. Equity Investment Returns: Bridgewest Ventures generates returns through equity investments in portfolio companies from Seed to Series B. The firm invests its own capital alongside external limited partners, targeting high-growth deep tech ventures in life sciences, medtech, AI/ML, clean tech, and advanced sensors.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

Bridgewest Ventures is a deep-tech venture capital firm and incubator operating the Bridgewest Venture Fund I LP, which invests Seed to Series B in New Zealand and Australian deep tech startups across life sciences, medtech, AI/ML, clean tech, and advanced sensors. The firm provides patient capital alongside active hands-on incubation support including executive-level advisors, governance assistance, talent recruitment, and IP strategy. Portfolio companies gain access to the Bridgewest Group's 25-year international network for scaling into global markets.

Product overview

Bridgewest Ventures operates as a deep tech incubator and venture capital firm backed by Bridgewest Group. The core offering consists of the Bridgewest Venture Fund I LP (a deep-tech venture fund targeting NZ/Australia innovation) and a Deep Tech Incubator Program in partnership with Callaghan Innovation that provides capital, executive advisors, and global network access to portfolio companies. The portfolio includes 14 companies spanning life sciences (BioOra - CAR-T cell therapy automation), MedTech (Avasa - arterial coupler, TheiaNova - corneal therapy, Luminoma - skin cancer screening, Nanophage - diagnostics), AI/ML (MACSO - sensory AI for agri-tech, The TestMart - AI test automation, Project DORIS - oncology LLM platform), clean tech (Compostify - bioplastics, ZealaFoam - plant-based packaging, Entropeak - battery technology), and advanced sensors. The annual Impactful Innovation conference connects the ecosystem. The firm connects New Zealand innovation with international markets and regulatory guidance needed to scale globally.

Differentiator

Problem solved

Functional benefit

Products and services

• Bridgewest Venture Fund I LP A deep-tech venture fund targeting New Zealand and Australian innovation companies seeking global expansion. Invests across life sciences, medical technology, artificial intelligence, advanced materials, and clean technology sectors. Available to wholesale investors including institutional investors, family offices, high-net-worth individuals, and international migrant investors.
• Deep Tech Incubator Program A technology incubator program operated in partnership with Callaghan Innovation that supports deep tech ventures from conception to global scale, providing capital, executive-level advisors, strategic governance, talent recruitment, IP strategy, and access to the Bridgewest Group's international network. For ambitious founders with breakthrough science in Life Sciences, MedTech, AI/ML, Clean Tech, and Advanced Sensors.
• Impactful Innovation Conference Bridgewest Ventures' flagship annual deep-tech conference connecting world-class founders, scientists, investors, and industry leaders. Showcases portfolio companies, attracts international attention, and serves as a key lever for the broader New Zealand deep-tech ecosystem.

Quantifiable outcome

• Fund I raised approximately NZ$60.2 million at first close, targeting NZ$100 million total.
• +3 more outcomes

Named customers12 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

Eleven partnerships are on record, tiered minor and core.

• Massey VenturesminorStrategic or Co-development Partner · 1 January 2022Massey Ventures is the commercialisation arm of Massey University. Bridgewest GM John Robson met Marina Rajič at Massey Ventures while she was a commercialisation manager there, which led to the genesis of BioViros. The relationship facilitated the identification of gaps in the NZ biotech ecosystem.
• Callaghan InnovationcoreStrategic or Co-development PartnerBridgewest Ventures is a Technology Incubator partner of Callaghan Innovation, the New Zealand government's innovation agency. The partnership provides success-based repayable grant funding for innovators to commercialize ideas with limited risk and no repayment required if the proposal doesn't work out. This partnership was established in 2020 as part of Bridgewest's deep-technology incubator program.
• Angel Association NZminorOthersBridgewest Ventures is a member of the Angel Association NZ, the champion for early-stage investment in New Zealand, which aims to build a thriving startup ecosystem by promoting angel investment as a rewarding, well-defined asset class.
• New Zealand Tech AllianceminorOthersMember of the NZ Tech Alliance, a unified voice for technology across New Zealand comprising over 20 diverse associations and hundreds of organizations working collaboratively to advance the national tech ecosystem.
• BIOTECH New ZealandminorOthersMember of BIOTECH New Zealand, a purpose-driven organization connecting innovators, investors, and researchers to maximize New Zealand's bioscience capability and grow a strong bioeconomy.
• NZ Private CapitalminorOthersMember of NZ Private Capital, the peak body for venture capital and private equity in New Zealand that facilitates the free flow of capital by connecting investors with business owners.
• BrinkminorImplementation/ SI/ Consulting PartnerEcosystem partner providing specialist digital design agency services. Brink pairs exceptional creativity with a deep understanding of business, science, and technology to help companies create effective digital experiences.
• HumankindminorImplementation/ SI/ Consulting PartnerEcosystem partner turning HR into a competitive advantage using proven frameworks and a unique Performance Partnership model to help deep tech ventures build culture, unlock high performance, and scale their teams.
• AcclimeminorImplementation/ SI/ Consulting PartnerEcosystem partner providing advisory, accounting, and corporate services to navigate regulatory complexity in New Zealand and Asia, ensuring corporate expansion is compliant and seamless.
• Young Enterprise Trust (YES)minorOthersBridgewest Ventures sponsors the YES Alumni programme and YES Alumni Awards, supporting young entrepreneurs and the next generation of NZ innovators.
• BioValeominorStrategic or Co-development PartnerBioValeo was commissioned and supported by Bridgewest Ventures as a Contract Research Organisation specialising in personalised medicines and immunotherapy-based clinical trials, addressing a critical gap in the NZ biotech ecosystem for clinical trial management supporting portfolio companies like BioOra.

Scale indicators7 records

Recent moves7 records

Expansion highlights7 records

Broad incumbents

• Founders Fund: US-based venture firm with deep tech and frontier technology exposure across biotech, aerospace, energy, and AI. Broad incumbent given overlapping deep tech thesis at much larger fund scale and US-anchored deal flow.
• Lux Capital: US-based venture firm investing in deep tech, science, and frontier technology including AI, biotech, advanced materials, and aerospace. Broad incumbent given direct deep tech category overlap, though at materially larger fund sizes and US-based deal flow.

Direct peers

• WNT Ventures: New Zealand's first regionally-backed venture fund focused on early-stage deep tech and clean tech companies. Direct peer given matching NZ geography, deep tech specialization, and seed-stage focus on science-derived IP.
• Main Sequence Ventures: Australia-based deep tech VC established by CSIRO, focused on translating scientific research into commercial outcomes across life sciences, advanced materials, and clean tech. Most comparable international peer given near-identical deep tech thesis, government-affiliated origins, and overlapping stage and sectors.
• Pacific Channel: New Zealand-based deep tech venture fund investing in life sciences, clean tech, and industrial technology at seed to Series A stage. Most directly comparable peer given identical NZ geography, deep tech focus, and stage, with overlapping LPs in the NZ venture ecosystem.
• Movac: New Zealand's largest dedicated deep tech and life sciences VC. Direct peer that has already co-invested alongside Bridgewest Ventures (e.g., led Avasa's NZ$4.75M Pre-Series-A), confirming directly overlapping deal flow and underwriting approach.
• Icehouse Ventures: New Zealand's largest angel and early-stage investor network, partnered with the Icehouse startup community. Direct peer given same NZ geography and seed/early-stage focus across tech and deep tech verticals.

Regional players

• AirTree Ventures: Australia-based early-to-growth stage VC backing tech founders across SaaS, marketplaces, and consumer. Regional peer given Australian geography and stage overlap, though less deep tech specificity.
• Blackbird Ventures: Australia's leading early-stage tech VC. Regional peer given shared Australia-NZ geography and stage focus, though broader tech mandate (consumer, fintech, SaaS) rather than deep tech specialization.
• Square Peg Capital: Australia and Israel-based VC investing from seed through growth across software, fintech, and tech-enabled businesses. Regional peer given geographic adjacency and overlapping early-stage mandate.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/bridgewestnz

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bridgewest Ventures